New Research Identifies Steps to Improve Gene Therapy Contracting and Patient Access Read more about New Research Identifies Steps to Improve Gene Therapy Contracting and Patient Access
Principles and Practices for Successful Gene Therapy Innovative Contracting: Insights From a Multistakeholder Convening Read more about Principles and Practices for Successful Gene Therapy Innovative Contracting: Insights From a Multistakeholder Convening
New Research Explores Gaps in Health Plan Implementation of FDA Label Revisions Read more about New Research Explores Gaps in Health Plan Implementation of FDA Label Revisions
The Timeliness of Health Plan Drug Coverage Policy Changes to FDA Label Revisions Read more about The Timeliness of Health Plan Drug Coverage Policy Changes to FDA Label Revisions
American Patients vs Foreign Governments — A Tale of 2 Value Sets Read more about American Patients vs Foreign Governments — A Tale of 2 Value Sets
Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA Read more about Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA
New Research Explores Future of Gene Therapy Financing in the U.S. Read more about New Research Explores Future of Gene Therapy Financing in the U.S.
Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program Read more about Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program
Unmet Need in the IRA Drug Price Negotiation Program Read more about Unmet Need in the IRA Drug Price Negotiation Program
New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives Read more about New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives